Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cannabidiol for Treating PTSD Symptoms and Neurocognitive Impairment in PTSD and PTSD Comorbid With TBI: A Placebo-controlled RCT With Neural-circuit Centered Precision Medicine Prediction of Response.

NCT04550377 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT04550377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04550377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cannabidiol for Treating PTSD Symptoms and Neurocognitive Impairment in PTSD and PTSD Comorbid With TBI: A Placebo-controlled RCT With Neural-circuit Centered Precision Medicine Prediction of Response.
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Recruiting
Start date
May 26, 2021
Completion date
June 30, 2026
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post traumatic stress disorder, traumatic brain injury